Latest filings (excl ownership)
8-K
Tharimmune Acquires Global License and Partners with Intract Pharma to Develop an Oral Formulation of Infliximab
16 Sep 24
10-Q
2024 Q2
Quarterly report
9 Aug 24
424B3
Prospectus supplement
23 Jul 24
EFFECT
Notice of effectiveness
22 Jul 24
S-3
Shelf registration
15 Jul 24
D
$2.08 mm in equity / options / securities to be acquired, sold $2.08 mm, 5 investors
28 Jun 24
8-K
Tharimmune Announces $2.08 Million Private Placement
20 Jun 24
S-8
Registration of securities for employees
12 Jun 24
8-K
Other Events
11 Jun 24
8-K
Entry into a Material Definitive Agreement
7 Jun 24
424B5
Prospectus supplement for primary offering
7 Jun 24
8-K
Tharimmune Announces 1-for-15 Reverse Stock Split
22 May 24
8-K
Submission of Matters to a Vote of Security Holders
14 May 24
10-Q
2024 Q1
Quarterly report
9 May 24
DEFA14A
Additional proxy soliciting materials
22 Mar 24
ARS
2023 FY
Annual report to shareholders
22 Mar 24
DEFA14A
Additional proxy soliciting materials
21 Mar 24
DEF 14A
Definitive proxy
21 Mar 24
PRE 14A
Preliminary proxy
11 Mar 24
8-K
Amendments to Articles of Incorporation or Bylaws
11 Mar 24
10-K
2023 FY
Annual report
23 Feb 24
8-K
Other Events
8 Feb 24
8-K
Other Events
12 Dec 23
8-K/A
Other Events
11 Dec 23
8-K
Other Events
8 Dec 23
8-K
Regulation FD Disclosure
6 Dec 23
424B5
Prospectus supplement for primary offering
28 Nov 23
EFFECT
Notice of effectiveness
28 Nov 23
8-K
Phase 1 ex-US trial achieved primary objective of predictable pharmacokinetic profiling with favorable safety and tolerability
27 Nov 23
CORRESP
Correspondence with SEC
27 Nov 23
CORRESP
Correspondence with SEC
27 Nov 23
CORRESP
Correspondence with SEC
24 Nov 23
CORRESP
Correspondence with SEC
24 Nov 23
FWP
Free writing prospectus
17 Nov 23
S-1/A
IPO registration (amended)
17 Nov 23
8-K
Tharimmune Announces 1-for-25 Reverse Stock Split
17 Nov 23
8-K
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard
16 Nov 23
UPLOAD
Letter from SEC
10 Nov 23
10-Q
2023 Q3
Quarterly report
7 Nov 23
8-K
Tharimmune Executes Exclusive Global Licensing Agreement for Innovative Clinical Stage Asset for Chronic Pruritis
7 Nov 23
Latest ownership filings
4
Kelly Anderson
12 Aug 24
4
Sireesh Appajosyula
12 Aug 24
4
Leonard L Mazur
12 Aug 24
4
Lynne A. Bui
12 Aug 24
4
RANDY MILBY
12 Aug 24
SC 13G/A
TANG CAPITAL PARTNERS LP
14 Feb 24
4
RANDY MILBY
18 Dec 23
SC 13G
TANG CAPITAL PARTNERS LP
7 Dec 23
4
RANDY MILBY
4 Dec 23
4
Lynne A. Bui
9 Nov 23
4
Sireesh Appajosyula
9 Nov 23
4
Kelly Anderson
9 Nov 23
4
Leonard L Mazur
9 Nov 23
3
Kelly Anderson
15 May 23
4/A
RANDY MILBY
13 Mar 23
4
RANDY MILBY
4 Jan 23
4
Sireesh Appajosyula
18 Jul 22
4
RANDY MILBY
21 Jun 22
4
RANDY MILBY
7 Jun 22
4
RANDY MILBY
2 Jun 22
4
RANDY MILBY
25 May 22
4
RANDY MILBY
23 May 22
4
RANDY MILBY
19 May 22
4
RANDY MILBY
19 Apr 22
3/A
RANDY MILBY
19 Apr 22
4
Leonard L Mazur
23 Mar 22
4
Lynne A. Bui
23 Mar 22
4
Sireesh Appajosyula
23 Mar 22
3
Varinder Kaur
27 Jan 22
4
RANDY MILBY
20 Jan 22
4
RANDY MILBY
20 Jan 22
4
RANDY MILBY
20 Jan 22
3/A
RANDY MILBY
20 Jan 22
4
Leonard L Mazur
18 Jan 22
3
Initial statement of insider ownership
13 Jan 22
3
RANDY MILBY
12 Jan 22
3
RANDY MILBY
12 Jan 22
3
RANDY MILBY
12 Jan 22
3
Surender Kharbanda
11 Jan 22
3
Sandeep Laumas
11 Jan 22